Showing results (51-60 of 94) with videos related to

Sort By:
Pageof 10
Arthritis and Rheumatism|October 2, 2002
Epitope-specific recognition of type II collagen by rheumatoid arthritis antibodies is shared with recognition by antibodies that are arthritogenic in collagen-induced arthritis in the mouseHarald Burkhardt, Tobias Koller, Ake Engström, et al.
The Journal of Rheumatology|December 17, 2015
Does Concomitant Methotrexate with Adalimumab Influence Treatment Outcomes in Patients with Psoriatic Arthritis? Data from a Large Observational StudyFrank Behrens, Michaela Koehm, Uta Arndt, et al.
Arthritis Research & Therapy|January 14, 2018
Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world settingRieke Alten, Harald Burkhardt, Eugen Feist, et al.
Arthritis Research & Therapy|June 17, 2006
Modulation of granulocyte-endothelium interactions by antileukoproteinase: inhibition of anti-type II collagen antibody-induced leukocyte attachment to the synovial endotheliumBettina Sehnert, Philip Gierer, Saleh Ibrahim, et al.
Rheumatology International|February 11, 2020
Individual therapeutic DAS28-dcrit responses differentiate between effectiveness of rheumatoid arthritis therapies and reflect patient-reported outcomes: retrospective analysis of DAS28 responses in comparative tocilizumab studiesMichaela Koehm, Matthew J McIntosh, Michael W Hofmann, et al.
Arthritis and Rheumatism|December 1, 2011
Tumor necrosis factor promoter polymorphism TNF*-857 is a risk allele for psoriatic arthritis independent of the PSORS1 locusEmiliano Giardina, Ulrike Hüffmeier, Jaya Ravindran, et al.
Arthritis and Rheumatism|May 29, 2007
TNF polymorphisms in psoriasis: association of psoriatic arthritis with the promoter polymorphism TNF*-857 independent of the PSORS1 risk alleleKristian Reich, Ulrike Hüffmeier, Inke R König, et al.
RMD Open|August 31, 2023
Impact of different classes of immune-modulating treatments on B cell-related and T cell-related immune response before and after COVID-19 booster vaccination in patients with immune-mediated diseases and primary immunodeficiency: a cohort studyMichaela Koehm, Maximilian Klippstein, Stephanie Dauth, et al.
Rheumatology Advances in Practice|February 11, 2022
Sarilumab reduces disease activity in rheumatoid arthritis patients with inadequate response to janus kinase inhibitors or tocilizumab in regular care in GermanyHans-Peter Tony, Eugen Feist, Peer Malte Aries, et al.
The Journal of Investigative Dermatology|September 19, 2008
Genetic variants of the IL-23R pathway: association with psoriatic arthritis and psoriasis vulgaris, but no specific risk factor for arthritisUlrike Hüffmeier, Jesús Lascorz, Beate Böhm, et al.
Pageof 10